• EN - English
  • SV - svenska
Parliamentary question - E-001031/2022(ASW)Parliamentary question
E-001031/2022(ASW)

    Answer given by Ms Kyriakides on behalf of the European Commission

    As regards a role of other nicotine products, the Commission is determined to follow up on the most robust scientific evidence in establishing a regulatory approach fully reflecting the objectives of the Europe’s Beating Cancer Plan[1].

    The Commission will draw, among others, on the Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) scientific opinion on electronic cigarettes, which found, on the one hand, supporting evidence for the harmful consequences of e-cigarettes consumption, and, on the other hand, weak evidence for the support of electronic cigarettes’ effectiveness in helping smokers to quit[2].

    The SCHEER opinion also underlined the important role e-cigarettes play in smoking initiation, which supports the careful and precautionary approach taken so far and will continue to support the Commission’s risk management and legislative decisions on e-cigarettes.

    Overall, smokeless and emerging tobacco and related products contain nicotine, a toxic and highly addictive substance — responsible for well-known health consequences — and they prolong the nicotine addiction[3].

    This is why these products are regulated and in the case of oral tobacco, banned in the EU[4]. On oral tobacco[5], the Commission does not envisage any change to its status.

    Last updated: 17 May 2022
    Legal notice - Privacy policy